dPCR, qPCR and RT-qPCR: Advantages and Challenges in Pre-clinical and Clinical Development
Eurofins Viracor Biopharma presented a webinar on October 13th, 11 am EST, titled "dPCR, qPCR and RT-qPCR: Advantages and Challenges in Pre-clinical and Clinical Development", presented by Manisha R. Diaz, PhD, Assoc. Dir. of R&D, Eurofins Viracor Biopharma and Deepak Tomar, PhD, Senior Scientific Lab Lead, Eurofins Bioanalytical Services
Regulated digital polymerase chain reaction (dPCR), quantitative polymerase chain reaction (qPCR) and reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) are extensively utilized to support biodistribution, vector shedding, gene expression, chimeric antigen receptor (CAR) T cell therapy and oncolytic viral bioanalytical studies.
In this presentation, the featured speakers will review the advantages and disadvantages of dPCR, qPCR and RT-qPCR as it relates to vaccine and biotherapeutic research. The featured speakers will also discuss the current method development and method validation best practices, context of use and level of regulatory compliance required to support bioanalysis in the pre-clinical and clinical settings.
Join this informative webinar to gain insights into the best use of PCR methods in the pre-clinical and clinical development of vaccines and other biotherapeutics.